Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

57 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Resistance detected in PBMCs predicts virological rebound in HIV-1 suppressed patients switching treatment.
Armenia D, Zaccarelli M, Borghi V, Gennari W, Di Carlo D, Giannetti A, Forbici F, Bertoli A, Gori C, Fabeni L, Pinnetti C, Marocco R, Latini A, Ceccherini-Silberstein F, Mastroianni CM, Mussini C, Antinori A, Perno CF, Santoro MM. Armenia D, et al. J Clin Virol. 2018 Jul;104:61-64. doi: 10.1016/j.jcv.2018.04.001. Epub 2018 Apr 3. J Clin Virol. 2018. PMID: 29738896
Secondary integrase resistance mutations found in HIV-1 minority quasispecies in integrase therapy-naive patients have little or no effect on susceptibility to integrase inhibitors.
Ceccherini-Silberstein F, Van Baelen K, Armenia D, Trignetti M, Rondelez E, Fabeni L, Scopelliti F, Pollicita M, Van Wesenbeeck L, Van Eygen V, Dori L, Sarmati L, Aquaro S, Palamara G, Andreoni M, Stuyver LJ, Perno CF. Ceccherini-Silberstein F, et al. Among authors: armenia d. Antimicrob Agents Chemother. 2010 Sep;54(9):3938-48. doi: 10.1128/AAC.01720-09. Epub 2010 May 17. Antimicrob Agents Chemother. 2010. PMID: 20479206 Free PMC article.
Prevalence of resistance mutations related to integrase inhibitor S/GSK1349572 in HIV-1 subtype B raltegravir-naive and -treated patients.
Malet I, Wirden M, Fourati S, Armenia D, Masquelier B, Fabeni L, Sayon S, Katlama C, Perno CF, Calvez V, Marcelin AG, Ceccherini-Silberstein F. Malet I, et al. Among authors: armenia d. J Antimicrob Chemother. 2011 Jul;66(7):1481-3. doi: 10.1093/jac/dkr152. Epub 2011 Apr 7. J Antimicrob Chemother. 2011. PMID: 21474479 Free article.
The HIV-1 integrase G118R mutation confers raltegravir resistance to the CRF02_AG HIV-1 subtype.
Malet I, Fourati S, Charpentier C, Morand-Joubert L, Armenia D, Wirden M, Sayon S, Van Houtte M, Ceccherini-Silberstein F, Brun-Vézinet F, Perno CF, Descamps D, Capt A, Calvez V, Marcelin AG. Malet I, et al. Among authors: armenia d. J Antimicrob Chemother. 2011 Dec;66(12):2827-30. doi: 10.1093/jac/dkr389. Epub 2011 Sep 19. J Antimicrob Chemother. 2011. PMID: 21933786
Study of genotypic and phenotypic HIV-1 dynamics of integrase mutations during raltegravir treatment: a refined analysis by ultra-deep 454 pyrosequencing.
Armenia D, Vandenbroucke I, Fabeni L, Van Marck H, Cento V, D'Arrigo R, Van Wesenbeeck L, Scopelliti F, Micheli V, Bruzzone B, Lo Caputo S, Aerssens J, Rizzardini G, Tozzi V, Narciso P, Antinori A, Stuyver L, Perno CF, Ceccherini-Silberstein F. Armenia D, et al. Among authors: d arrigo r. J Infect Dis. 2012 Feb 15;205(4):557-67. doi: 10.1093/infdis/jir821. Epub 2012 Jan 11. J Infect Dis. 2012. PMID: 22238474 Free PMC article.
The lowest X4 Geno2Pheno false-positive rate is associated with greater CD4 depletion in HIV-1 infected patients.
Santoro MM, Armenia D, Fabeni L, Santoro M, Gori C, Forbici F, Svicher V, Bertoli A, Dori L, Surdo M, Balestra E, Palamara G, Girardi E, Angarano G, Andreoni M, Narciso P, Antinori A, Ceccherini-Silberstein F, Perno CF. Santoro MM, et al. Among authors: armenia d. Clin Microbiol Infect. 2012 Aug;18(8):E289-98. doi: 10.1111/j.1469-0691.2012.03905.x. Epub 2012 Jun 8. Clin Microbiol Infect. 2012. PMID: 22681969 Free article.
The genotypic false positive rate determined by V3 population sequencing can predict the burden of HIV-1 CXCR4-using species detected by pyrosequencing.
Svicher V, Cento V, Rozera G, Abbate I, Santoro MM, Armenia D, Fabeni L, Bruselles A, Latini A, Palamara G, Micheli V, Rizzardini G, Gori C, Forbici F, Ippolito G, Andreoni M, Antinori A, Ceccherini-Silberstein F, Capobianchi MR, Perno CF. Svicher V, et al. Among authors: armenia d. PLoS One. 2013;8(1):e53603. doi: 10.1371/journal.pone.0053603. Epub 2013 Jan 14. PLoS One. 2013. PMID: 23341955 Free PMC article.
Impact of pre-therapy viral load on virological response to modern first-line HAART.
Santoro MM, Armenia D, Alteri C, Flandre P, Calcagno A, Santoro M, Gori C, Fabeni L, Bellagamba R, Borghi V, Forbici F, Latini A, Palamara G, Libertone R, Tozzi V, Boumis E, Tommasi C, Pinnetti C, Ammassari A, Nicastri E, Buonomini A, Svicher V, Andreoni M, Narciso P, Mussini C, Antinori A, Ceccherini-Silberstein F, Di Perri G, Perno CF. Santoro MM, et al. Among authors: armenia d. Antivir Ther. 2013;18(7):867-76. doi: 10.3851/IMP2531. Epub 2013 Jan 23. Antivir Ther. 2013. PMID: 23343501 Free article.
Identification of a rare mutation at reverse transcriptase Lys65 (K65E) in HIV-1-infected patients failing on nucleos(t)ide reverse transcriptase inhibitors.
Fourati S, Visseaux B, Armenia D, Morand-Joubert L, Artese A, Charpentier C, Van Den Eede P, Costa G, Alcaro S, Wirden M, Perno CF, Ceccherini Silberstein F, Descamps D, Calvez V, Marcelin AG. Fourati S, et al. Among authors: armenia d. J Antimicrob Chemother. 2013 Oct;68(10):2199-204. doi: 10.1093/jac/dkt200. Epub 2013 Jun 7. J Antimicrob Chemother. 2013. PMID: 23749955
57 results